Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Rheumatology

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/RHEUMATOLOGY/KEH470PMID 15637037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.

  2004cited by this paper
• A common pathway in periodic fever syndromes.

  2004cited by this paper
• Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases.

  2004cited by this paper
• Efficacy and safety of rituximab in type II mixed cryoglobulinemia.

  2003cited by this paper
• The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations

  2003cited by this paper
• Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.

  2003cited by this paper
• Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway

  2003cited by this paper
• Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.

  2003cited by this paper
• Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder.

  2002cited by this paper
• Rituximab‐induced serum sickness

  2002cited by this paper
• Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab).

  2001cited by this paper
• Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

  1999cited by this paper
• A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome.

  1997cited by this paper
• "Streaking leukocyte factor," arthritis, and pyoderma gangrenosum.

  1975cited by this paper

• Interrupting an IFN-γ-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne

  2024cites this paper
• Inflammasome-Dependent Cytokines at the Crossroads of Health and Autoinflammatory Disease.

  2019cites this paper
• Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome

  2018cites this paper
• Rituximab in the treatment of skin diseases

  2017cites this paper
• Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome.

  2016cites this paper
• Rituximab-induced serum sickness: A systematic review.

  2015influential citation
• Novel applications of Rituximab in dermatological disorders

  2014cites this paper
• Monogenic autoinflammatory diseases.

  2014cites this paper
• Critical role for inflammasome-independent IL-1β production in osteomyelitis

  2013cites this paper
• The Role of Rituximab in the Therapy of Mixed Cryoglobulinemia

  2012cites this paper
• Long-Term Course of Patients with Mixed Cryoglobulinemia

  2012cites this paper
• A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.

  2012cites this paper
• Extrahepatic Manifestations of Chronic HCV

  2012cites this paper
• Rituximab-induced serum sickness in a patient with refractory chronic immune thrombocytopenic purpura: a case report and review of the literature

  2011cites this paper
• Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.

  2011cites this paper
• Rituximab Therapy to Prevent Relapse in Chronic Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Child

  2011cites this paper
• Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.

  2011cites this paper
• Rituximab‐induced serum sickness in refractory immune thrombocytopenic purpura

  2011cites this paper
• Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature

  2011cites this paper
• Rituximab plus Peg-interferon- (cid:1) /ribavirin compared with Peg-interferon-(cid:1) /ribavirin in hepatitis C–related mixed cryoglobulinemia Treatment of hepatitis C (HCV)–mixed

  2010cites this paper
• Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.

  2010cites this paper
• Rituximab‐induced vasculitis: A case report and review of the medical published work

  2009cites this paper
• Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.

  2009cites this paper
• Allergies aux médicaments des biothérapies : les données épidémiologiques

  2009cites this paper
• Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura

  2009cites this paper
• Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.

  2009cites this paper
• Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis

  2008cites this paper
• Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.

  2008cites this paper
• Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis

  2008cites this paper
• Serum sickness following a first rituximab infusion with no recurrence after the second one.

  2008cites this paper
• Serum Sickness in a Patient With Follicular Lymphoma After Rituximab and Radioimmunotherapy With Ibritumomab Tiuxetan

  2007cites this paper
• Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra

  2007cites this paper
• Serum sickness following treatment with rituximab.

  2007cites this paper
• Rituximab-induced serum sickness in a patient with follicular lymphoma

  2007cites this paper
• Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists

  2007cites this paper
• Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation.

  2007cites this paper
• Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade

  2007cites this paper
• Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?

  2007cites this paper
• [Not Available].

  2006cites this paper
• El papel de rituximab en el tratamiento de la artritis reumatoide

  2006cites this paper
• Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia.

  2006cites this paper
• Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome

  2006cites this paper
• New therapies for systemic lupus erythematosus: cellular targets.

  2006cites this paper
• Blocking IL-1 in systemic inflammation

  2005cites this paper